Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07488845
Starting soon Not applicable

Management of Vascular Complications in Pediatric Supracondylar Humerus Fractures

NCT07488845 · tracked via the Priya Life Science Egypt tracker
Sponsor
Assiut University
Phase
Not applicable
Started
2026-04-01
Last updated
2026-03-23

Condition(s) studied

Vascular ComplicationsSupracondylar Humerus Fracture

Investigational drug(s) / intervention(s)

vascular exploration

vascular exploration: Patients with no pulse or distal doppler signals, and delayed capillary refill time will undergo immediate vascular exploration and injuries will be documented and managed accordingly.

Study summary

* To determine the incidence and types of vascular injuries associated with pediatric supracondylar humerus fractures.
* Identify outcomes of different management strategies
* Identify risk factors for vascular injury

Eligibility

Sex
ALL
Min age
—
Max age
15 Years
Healthy volunteers
No
Inclusion Criteria: * ● Children Diagnosed with supracondylar humerus fracture (Gartland I-IV) aged under 15 years. * Presented within 1st 48 hrs of injury. Exclusion Criteria: * ● Old trauma \>48 hours * Previous vascular intervention in the same limb * Another fracture in the same limb

Primary outcome measure(s)

  • incidence of vascular complications in patients with supracondylar humerus fractures — baseline

Trial sites (1)

FacilityCityRegionStatus
Assiut University Asyut Egypt

More Assiut University trials in Egypt

Combined Hystroscopic and Laparoscopic Repair of CS Scar Disorder Recruiting
The Outcome of Inserting Intercostal Tube or Pleurodesis for Malignant Pleural Effusion Starting soon
Maternal Iron Deficiency and/or Iron Deficiency Anemia to Neonatal Hemoglobin Concentration and Iron Stores Starting soon
Real-Time (TRUS) Guidance in Endoscopic Treatment of BPH Starting soon
Intraoperative Lidocaine Infusion Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07488845 on ClinicalTrials.gov ↗ ← All trials in Egypt